Loading the section…

LAB: financial statements from SEC — TradeAlmanac

LAB

Standard BioTools Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024
Revenue	85M	91M
Cost of revenue	43M	46M
Gross profit	43M	45M
Research and development	26M	29M
Selling, general and administrative	110M	103M
Operating expenses	153M	172M
Operating income	−110M	−127M
Interest expense	26,000	3M
Pre-tax income	−97M	−90M
Income tax	−38M	542,000
Net income	−75M	−139M
Earnings per share	−0.20	−0.52
Earnings per share, diluted	−0.20	−0.52
Weighted average shares	382M	353M
Weighted average shares, diluted	382M	353M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	266M	121M	129M	159M	151M	167M	212M	271M
Receivables	17M	13M	14M

Cash flow

Metric	31/12/2025	31/12/2024
Operating cash flow	−74M	−143M
Depreciation and amortisation	9M	13M
Share-based compensation	30M	32M
Capital expenditure	8M	8M
Investing cash flow	27M	363M
Share buybacks	0	40M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator